Money Too Tight To Mention At Motif After Iclaprim 'No' From FDA
Executive Summary
Hit with a complete response letter from the US FDA for its antibiotic to treat ABSSSI, Motif needs to raise funds and fast to stay afloat and prepare a meeting package to discuss the next steps for iclaprim with the agency.